Last reviewed · How we verify
AIGIV
At a glance
| Generic name | AIGIV |
|---|---|
| Also known as | ANTHRASIL® |
| Sponsor | Emergent BioSolutions |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AIGIV CI brief — competitive landscape report
- AIGIV updates RSS · CI watch RSS
- Emergent BioSolutions portfolio CI